The pathophysiology of oxaliplatin-induced neurotoxicity
- PMID: 17073636
- DOI: 10.2174/092986706778521904
The pathophysiology of oxaliplatin-induced neurotoxicity
Abstract
Nerve dysfunction is a common accompaniment of chemotherapy, typically occurring in a dose-dependent manner, so that the higher the dose and the longer the time of exposure, the more likely neuropathy is to occur. With the majority of chemotherapies, the mechanisms of neurotoxicity have not been clearly established. Cessation of therapy may prevent progression to a more severe syndrome and is often necessary even if there has been tumour response. Alternatively dose reduction may slow or halt progression. The clinical investigation of patients with suspected nerve dysfunction related to chemotherapy remains problematic. While routine nerve conduction studies can document the presence of a neuropathy, they do not provide further insight into pathophysiology. In contrast, measurements of nerve excitability by threshold tracking provide complementary information to conventional nerve conduction studies and may be used to infer the activity of a variety of ion channels, energy-dependent pumps and ion exchange processes activated during the process of impulse conduction. The present review will focus on recent developments in clinical rating scales and novel neurophysiological methods for the clinical investigation of chemotherapy-induced neurotoxicity, and will highlight how such methods may prove useful to study the neurological effects of chemotherapy. Specific emphasis will be placed on oxaliplatin, a platinum-based chemotherapy effective for colorectal cancer that exhibits dose-limiting neurotoxicity.
Similar articles
-
Nerve excitability assessment in chemotherapy-induced neurotoxicity.J Vis Exp. 2012 Apr 26;(62):3439. doi: 10.3791/3439. J Vis Exp. 2012. PMID: 22565594 Free PMC article.
-
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.Brain. 2009 Oct;132(Pt 10):2712-23. doi: 10.1093/brain/awp219. Epub 2009 Sep 10. Brain. 2009. PMID: 19745023
-
Impact of oxaliplatin-induced neuropathy: a patient perspective.Support Care Cancer. 2012 Nov;20(11):2959-67. doi: 10.1007/s00520-012-1428-5. Epub 2012 Mar 17. Support Care Cancer. 2012. PMID: 22426503
-
Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers.Clin Colorectal Cancer. 2014 Jun;13(2):73-80. doi: 10.1016/j.clcc.2013.11.004. Epub 2013 Nov 13. Clin Colorectal Cancer. 2014. PMID: 24365057 Review.
-
Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.Curr Med Chem. 2008;15(29):3081-94. doi: 10.2174/092986708786848569. Curr Med Chem. 2008. PMID: 19075655 Review.
Cited by
-
Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.Contemp Oncol (Pozn). 2012;16(1):72-8. doi: 10.5114/wo.2012.27341. Epub 2012 Feb 29. Contemp Oncol (Pozn). 2012. PMID: 23788859 Free PMC article.
-
Peripheral nerve axonal excitability studies: expanding the neurophysiologist's armamentarium.Cerebellum Ataxias. 2015 Mar 3;2:4. doi: 10.1186/s40673-015-0022-2. eCollection 2015. Cerebellum Ataxias. 2015. PMID: 26331047 Free PMC article.
-
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Pharmacogenomics J. 2013 Oct;13(5):403-9. doi: 10.1038/tpj.2012.31. Epub 2012 Aug 7. Pharmacogenomics J. 2013. PMID: 22868256 Free PMC article.
-
Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.J Pain. 2009 May;10(5):534-41. doi: 10.1016/j.jpain.2008.12.003. Epub 2009 Feb 23. J Pain. 2009. PMID: 19231296 Free PMC article.
-
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.Oncol Ther. 2021 Dec;9(2):385-450. doi: 10.1007/s40487-021-00168-y. Epub 2021 Oct 16. Oncol Ther. 2021. PMID: 34655433 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources